VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NUTXNutex Health, Inc.
$172.74$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NUTX
  4. Financial Ratios

Nutex Health, Inc. (NUTX) Financial Ratios

Latest Ratios: P/E Ratio 7.4x · EV/EBITDA 4.1x · ROE 22.6%. (2010–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NUTX Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.2B$1.1B$162M$119M$1.2B——————
Enterprise Value$1.4B$1.3B$458M$373M$1.4B——————
P/E Ratio →7.3915.713.26————————
P/S Ratio1.491.270.340.485.50——————
P/B Ratio2.762.630.801.5010.02——————
P/FCF4.724.537.75—33.53——————
P/OCF4.794.486.9894.7323.84——————

P/E links to full P/E history page with 30-year chart

NUTX EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.460.951.516.56——————
EV / EBITDA4.074.323.06————————
EV / EBIT4.914.793.53————————
EV / FCF—5.2021.98—40.01——————

NUTX Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin50.8%50.8%40.9%14.0%7.0%54.1%57.5%58.6%62.8%-2336.2%—
Operating Margin31.5%31.5%27.2%-12.8%-185.4%51.4%55.9%35.8%-61.5%-10165.0%—
Net Profit Margin8.1%8.1%10.9%-18.5%-193.7%40.0%38.7%21.6%-205.9%2512.6%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE22.6%22.6%37.1%-45.9%-272.4%78.2%106.9%84.8%-645.7%24.6%—
ROA9.0%9.0%9.9%-11.0%-102.8%37.7%43.4%23.3%-149.0%30.3%-182.4%
ROIC38.0%38.0%23.6%-6.9%-88.7%42.1%52.8%32.0%-50.2%——
ROCE43.2%43.2%30.6%-8.9%-110.8%53.7%79.7%65.2%-94.7%-99.4%—

NUTX Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.830.831.693.492.220.931.022.36—0.16—
Debt / EBITDA1.191.192.27——1.000.943.23———
Net Debt / Equity—0.391.473.211.940.740.852.20—0.16—
Net Debt / EBITDA0.560.561.98——0.800.783.01———
Debt / FCF—0.6814.23—6.481.044.89————
Interest Coverage12.0112.016.51-1.97-32.6028.3523.6610.09-7.65-15.35-173.90

NUTX Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.413.412.081.561.794.094.310.630.290.060.08
Quick Ratio3.393.392.061.501.724.014.250.620.270.060.08
Cash Ratio1.181.180.310.380.620.960.810.110.110.010.00
Asset Turnover—0.950.730.620.510.840.890.543.040.01—
Inventory Turnover150.38150.3899.5562.7857.7054.1067.4644.6318.77——
Days Sales Outstanding—135.71179.5292.5297.06126.34144.04135.9149.7098.54—

NUTX Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield6.4%6.7%4.0%4.4%4.2%——————
Payout Ratio104.9%104.9%12.3%——108.9%55.7%90.3%———

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield13.5%6.4%30.6%————————
FCF Yield21.2%22.1%12.9%—3.0%——————
Buyback Yield0.4%0.4%0.0%0.0%0.0%——————
Total Shareholder Yield6.8%7.1%4.0%4.4%4.2%——————
Shares Outstanding—$7M$5M$4M$4M$4M$4M$4M$7M$4M$2M

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Earnings quality and cash volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Discounted Multiples Reflect Earnings Skepticism

Based on Nutex's reported figures, the trailing P/E of 7.42 and EV/EBITDA of 4.09 sit well below the 20.57 P/E and 14.12 EV/EBITDA of peer Addus HomeCare, suggesting the market is pricing in durability doubts about recent profits.

The forward P/E of 6.35 sits below the trailing multiple, which implies the market expects earnings to hold or grow despite the recent year-over-year revenue decline of 18.7%. The 6.3% dividend yield and 4.74 P/FCF multiple suggest investors are being compensated for volatility, though whether the discount reflects a mispricing or a rational response to lumpy cash generation warrants further investigation.

Operating Margins Outrun Net Earnings Power

According to reported quarterly figures, Nutex's operating margin of 35.4% in 2026Q3 compares with a net margin of 18.5%, a gap that appears driven by below-the-line items rather than core operations.

Operating margin swung from 13.8% to 57.8% across recent quarters, indicating that headline profitability is highly sensitive to volume and cost timing rather than a stable structural level. The persistent gap between operating and net margin suggests interest, amortization, or other non-operating charges may be absorbing a meaningful share of earnings, and investors should monitor whether this drag narrows as the network scales.

Returns Oscillate Without Clear Compounding

Based on reported figures, ROIC moved from 1.2% in 2024Q2 to 20.5% in 2024Q4 and 8.9% in 2026Q3, a pattern that suggests returns are episodic rather than compounding.

The trajectory indicates that return on invested capital is driven more by margin spikes than by consistent asset efficiency, given asset turnover of roughly 0.2 across quarters. Compared with peer AMERISAFE's 21.9% ROIC, Nutex's current 8.9% appears modest, implying the capital base may not yet be generating returns commensurate with its facility footprint.

Leverage Easing as Equity Rebuilds

As reported in financial statements, Nutex's debt-to-equity ratio fell from 3.80 in 2024Q3 to 0.67 in 2026Q3, while interest coverage strengthened to 15.92x, indicating debt service has become considerably more comfortable.

Absolute debt has remained broadly flat near $340M to $390M, so the improvement in leverage ratios appears to be driven primarily by equity growth rather than debt reduction. Net debt to EBITDA of 4.41 remains elevated in absolute terms, and refinancing exposure cannot be assessed from the provided data alone.

Cash Buffer Strong but Quarterly Swings

Based on Nutex's reported figures, a current ratio of 4.76 and cash of $249.9M in 2026Q3 indicate ample short-term coverage, though cash has ranged from $40.8M to $249.9M across the ten quarters.

The quick ratio of 4.72 is nearly identical to the current ratio, which suggests inventory is negligible and liquidity depends on receivables and cash rather than physical stock. Because working capital timing dominates quarterly cash flow, the liquidity position may look far weaker under a period of slowed collections, which warrants monitoring.

Headline Margins Mask Earnings Volatility

Based on reported quarterly figures, Nutex's 2026Q3 operating margin of 35.4% and ROIC of 8.9% may overstate durable earning power, given swings from 13.8% to 57.8% in operating margin over recent quarters.

The most commonly misapplied ratio for a micro-hospital operator is the headline operating margin, which captures fixed-cost leverage at a single point in a volatile volume cycle rather than normalized earning power. Investors should instead anchor on trailing multi-quarter averages of operating margin and free cash flow after working capital changes, which better reflect the reimbursement and collection timing that drives quarterly results.

Download Financial Ratios Data

Includes 30+ ratios · 13 years · Updated daily

Consensus & Technical Research Suite
Open NUTX Terminal

NUTX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

What is Nutex Health, Inc.'s P/E ratio?

Nutex Health, Inc.'s current P/E ratio is 7.4x. The historical average is 9.5x. This places it at the 50th percentile of its historical range.

What is Nutex Health, Inc.'s EV/EBITDA?

Nutex Health, Inc.'s current EV/EBITDA is 4.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.7x.

What is Nutex Health, Inc.'s ROE?

Nutex Health, Inc.'s return on equity (ROE) is 22.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 2.5%.

Is NUTX stock overvalued?

Based on historical data, Nutex Health, Inc. is trading at a P/E of 7.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Nutex Health, Inc.'s dividend yield?

Nutex Health, Inc.'s current dividend yield is 6.36% with a payout ratio of 104.9%.

What are Nutex Health, Inc.'s profit margins?

Nutex Health, Inc. has 50.8% gross margin and 31.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Nutex Health, Inc. have?

Nutex Health, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.